All In Biotech

Drug Trial Radar · NCT02304783

Oral NSAI Versus Paracetamol or Placebo as a Second Line Treatment for Renal Colics

The Investigation of the Efficacity and Safety of Oral Non Steroidal Anti Inflammatory (NSAI) Drugs Such as Piroxicam as a Second Line Treatment of Patients Consulting the Emergency Departement for Renal Colics.

Last checked: Nov 19, 2026Latest source record: Apr 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,400 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,400

Actual

Start

Jan 2014

Primary completion

Jun 2021

Study completion Dec 2021

Sponsor

Lead sponsor
University of MonastirAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 2, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Outpatients treatment with NSAI in renal colics has not been well investigated and there is no clear recommendations regarding this matter. The aim of this study is to determine if an oral NSAI treatment is beneficial in patients discharged for the emergency departement after the first line treatment of a renal colic investigating the recurrence of pain, the reconsultation rates and the admissions.

Conditions

  • Renal Colic

Interventions

  • PiroxicamDrug

    Patients allocated to this arm received, as a second line treatment of renal colics, a five days treatment with 20 mg piroxicam associated with placebo per day and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.

  • PlaceboDrug

    Patients allocated to this arm received a five days treatment with Placebo and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.

  • paracetamolDrug

    Patients allocated to this arm received a five days treatment with Paracetamol and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacity of oral NSAI (telephone call, asking for the recurrence of pain, the reconsultation rates and intervals and the need for other treatments)Time frame: seven days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Emergency Department of University Hospital of Monastir

    Monastir, Tunisia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.